|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cyclooxygenase-2 polymorphisms and the risk of esophageal adeno-or squamous cell carcinoma显示文摘AIM:To determine whether-1195 A→G and/or-765 G→C polymorphisms in Cyclooxygenase-2(COX-2 ) may have a risk modifying effect on the development of esophageal carcinoma in a Dutch Caucasian population.METHODS:Two study groups were recruited, 252 patients with esophageal carcinoma and 240 healthy controls, matched for race, age, gender and recruiting area.DNA was isolated from whole blood and used for genotyping.PCR products were digested with restriction enzymes and products were analyzed by agarose gel electrophoresis.Odds ratios(OR) and 95% confldence intervals(CI) were estimated.RESULTS:The distribution of the-1195 A→G polymorphism was signif icantly different in esophageal cancer patients compared to controls.The-1195 GG genotype resulted in a higher risk of developing esophageal adenocarcinoma(OR = 3.85, 95% CI:1.45-10.3) compared with the-1195 AA genotype as a reference.The-765 G→C genotype distribution was not different between the two groups.The GG/ GG haplotype was present more often in esophageal adenocarcinoma patients than in controls(OR = 3.45, 95% CI:1.24-9.58;with AG/AG as a reference).The same trends were observed in patients with squamous cell carcinomas, however, the results did not reach statistical signif icance.CONCLUSION:Presence of the COX-2-1195 GG genotype and of the GG/GG haplotype may result in a higher risk of developing esophageal carcinoma. | Jón O Kristinsson Paul van Westerveld Rene HM te Morsche Hennie MJ Roelofs T Wobbes Ben JM Witteman Adriaan CITL Tan Martijn GH van Oijen Jan BMJ Jansen Wilbert HM Peters | 2009 | World Journal of Gastroenterology2009，15，28： | 11 |
| 2 | Factors influencing the miss rate of polyps in a back-to-back colonoscopy study显示文摘 | A. Leufkens M. van Oijen F. Vleggaar P. Siersema | 2012 | Endoscopy2012，，05： | 3 |
| 3 | Random Comparison of Guaiac and Immunochemical Fecal Occult Blood Tests for Colorectal Cancer in a Screening Population显示文摘 | Leo G. van Rossum Anne F. van Rijn Robert J. Laheij Martijn G. van Oijen Paul Fockens Han H. van Krieken Andre L. Verbeek Jan B. Jansen Evelien Dekker | 2008 | Gastroenterology2008，，1： | 2 |
| 4 | Endoscopic Trimodal Imaging Detects Colonic Neoplasia as Well as Standard Video Endoscopy显示文摘 | Teaco Kuiper Frank J.C. van den Broek Anton H. Naber Ellert J. van Soest Pieter Scholten Rosalie Ch. Mallant–Hent Jan van den Brande Jeroen M. Jansen Arnoud H.A.M. van Oijen Willem A. Marsman Jacques J.G.H.M. Bergman Paul Fockens Evelien Dekker | 2011 | Gastroenterology2011，，7： | 2 |
| 5 | Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: Results of a systematic review显示文摘AIM:To investigate adherence rates in tumor necrosis factor-α (TNF-α)-inhibitors in Crohn's disease (CD) and rheumatoid arthritis (RA) by systematic review of medical literature. METHODS:A structured search of PubMed between 2001 and 2011 was conducted to identify publications that assessed treatment with TNF-α inhibitors providing data about adherence in CD and RA. Therapeutic agents of interest where adalimumab, infliximab and etanercept, since these are most commonly used for both diseases. Studies assessing only drug survival or continuation rates were excluded. Data describing adherence with TNF-α inhibitors were extracted for each selected study. Given the large variation between definitions of measurement of adherence, the definitions as used by the authors where used in our calculations. Data were tabulated and also presented descriptively. Sample size-weighted pooled proportions of patients adherent to therapy and their 95%CI were calculated.To compare adherence between infliximab, adalimumab and etanercept, the adherence rates where graphed alongside two axes. Possible determinants of adherence were extracted from the selected studies and tabulated using the presented OR. RESULTS:Three studies on CD and three on RA were identified, involving a total of 8147 patients (953 CD and 7194 RA). We identified considerable variation in the definitions and methodologies of measuring adherence between studies. The calculated overall sample size-weighted pooled proportion for adherence to TNF-α inhibitors in CD was 70% (95%CI:67%-73%) and 59% in RA (95%CI:58%-60%). In CD the adherence rate for infliximab (72%) was highercompared to adalimumab (55%), with a relative risk of 1.61 (95%CI:1.27-2.03), whereas in RA adherence for adalimumab (67%) was higher compared to both infliximab (48%) and etanercept (59%), with a relative risk of 1.41 (95%CI:1.3-1.52) and 1.13 (95%CI:1.10-1.18) respectively. In comparative studies in RA adherence to infliximab was better than etanercept and etanercept did better than adalimumab. In three studies, the most consistent factor associated with lower adherence was female gender. Results for age, immunomodulator use and prior TNF-α inhibitors use were conflicting. CONCLUSION:One-third of both CD and RA patients treated with TNF-α inhibitors are non-adherent. Female gender was consistently identified as a negative determinant of adherence. | Herma H Fidder Maartje MJ Singendonk Mike van der Have Bas Oldenburg Martijn GH van Oijen | 2013 | World Journal of Gastroenterology2013，19，27： | 2 |
| 6 | Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large dutch cohort study显示文摘 | van Boxel OS van Oijen MG Hagenaars MP | 2010 | Am J Gastroenterol2010，105，11： | 1 |
| 7 | Modelling ofpremixed laminar flames using flamelet-generated manifolds 显示文摘 | Van Oijen J De Goey L | 2000 | Combust- ion Science and Technology2000，161，1： | 1 |
| 8 | Modeling of complex premixed burner systems by using flamelet-generated manifolds 显示文摘 | VAN OIJEN J A LAMMERS F A DE GOEY I P H | 2001 | Combustion and Flame2001，127，： | 1 |
| 9 | Genetic polymorphisms in GSTA1, GSTP1, GSTT1, and GSTMI and gastric cancer risk in a Vietnamese population 显示文摘 | NGUYEN T V JANSSEN M J VAN OIJEN M G | 2010 | Oncol Res2010，18，7： | 1 |
| 10 | Measurements of the absolute concentrations of HCO and 1CH2 in a premixed atmospheric flat flame by cavity ring-down spectroscopy显示文摘 | Evertsen R Van Oijen J A Hermanns R T E | 2003 | Combust Flame2003，135，12： | 1 |
| 11 | ln situ detection of virus-andtumor-specific T-cell immunity显示文摘 | Haanen JBAC van Oijen MGCT tirion F | 2000 | Nat Med2000，6，： | 1 |
| 12 | Antral glutathione concentration and glutathione-S-transferase activity in patients with and without helicobacter pylori显示文摘 | Verhulst M L van Oijen A H Roelofs H M | 2000 | Dig Dis Sci2000，45，3： | 1 |
| 13 | Endocytosis by random initiation and stabilization of clathrin-coated pits 显示文摘 | Ehrlich M Boll W van Oijen A | 2004 | 118:591-6052004，118，： | 1 |
| 14 | Unrecognized myo- cardial infarction in relation to risk of dementia and cerebral small vessel disease显示文摘 | Ikram MA van Oijen M de Jong F J | 2008 | Stroke2008，39，5： | 1 |
| 15 | Factors influencing the miss rate of polyps in a back-to-back colonoscopy study显示文摘 | Leufkens AM van Oijen MG Vleggaar FP | 2012 | Endoscopy2012，44，5： | 1 |
| 16 | Modelling of Premixed Laminar Flames Using Flamelet-Generated Manifolds 显示文摘 | Oijen J V Goey L D | 2000 | Com- bustion Science and Technology2000，161，1： | 1 |
| 17 | Prognostic value of free plasma homocysteine levels in patients hospitalized with acute coronary syndrome 显示文摘 | Van Oijen MG Claessen BE Clappers N | 2008 | Am J Cardiol2008，102，2： | 1 |
| 18 | Antral glutathion concentrtion and glutathione S-transferase activity in patients with and without Helicobacter pylori显示文摘 | Verhulst ML Oijen AHAMV Roelofs HMJ | 2000 | Digestive Dis and Sci2000，45，： | 1 |
| 19 | Overexpression of c-Src in areas of hyperproliferation in head and neck cancer,premalignant lesions and benign mucosal disorders显示文摘 | Van Oijen MG Rijksen G ten Broek FW | 1998 | J Oral Pathol Med1998，27，4： | 1 |
| 20 | Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study显示文摘 | van BOXEL 0 S van OIJEN M G HAGENAARS M P | 2010 | AmJ Gastroenterol2010，105，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员